-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The environment of the pharmaceutical industry is changing more and more rapidly, and at the same time, the flow of executives of pharmaceutical companies has begun to accelerate significantly in recent years
.
From the current point of view, the changes in the executives of such pharmaceutical companies are becoming more frequent in 2022
.
On the 19th, Seri Medical issued an announcement stating that Liu Yuan applied for his resignation as the secretary of the company's board of directors and securities affairs representative due to personal reasons.
After resigning from the above-mentioned positions, he still serves as the deputy general manager
.
It is understood that Liu Yuan has held this position in the company since March 28, 2019
.
According to the data, Seri Medical was established on February 23, 2004.
Its main business is intensive sales, simple sales, and research and development, production and sales of independent in vitro diagnostic products
.
In recent years, its personnel changes are also more frequent
.
In August last year, a number of senior executives changed, involving the chief financial officer and general manager
.
On the 18th, Marc CROUTON, Chief Commercial Officer of the Fresenius Kabi Management Committee, and Ulf JASSON, Executive Vice President of the Asia Pacific Region, announced to the employees a personnel appointment, which will be executed by Fresenius Kabi China from February 1, 2022.
Zhuang Wenyan, vice president and general manager of Fresenius Kabihuarui Pharmaceuticals, temporarily leads the business of Feka in China
.
It is understood that Fresenius Kabi announced last month that Mr.
Ding Weibo, President of China, has decided to accept external development opportunities and will officially resign on February 1, 2022
.
According to Fresenius Kabi's original plan, after Ding Weibo leaves office, Ulf Jansson, Executive Vice President of Fresenius Kabi Asia Pacific, will also serve as President of Fresenius Kabi China
.
However, due to the ongoing epidemic, under the influence of this, Ulf Jansson's business trip to and from China has great uncertainty, so he made this new appointment
.
In addition, Fresenius Kabi has also promoted two business division heads this time.
Chen Guang, the current head of the parenteral nutrition and anesthesia division, will be promoted to the executive vice president of Fresenius Kabi Huarui Pharmaceuticals.
General Manager Shen Minyue, the current head of the General Business Division, will be promoted to General Manager of Beijing Fresenius Kabi Pharmaceutical Co.
, Ltd.
.
Linglu Pharmaceutical has also announced new personnel appointments recently, and its co-founder Zhang Xiaolei has become a full-time CEO
.
It is understood that Zhang Xiaolei will serve as the interim CEO of Linglu since May 2021; in addition, Linglu has also appointed Dr.
John Maraganore, the former founder and CEO of Alnylam, and Dr.
Peter Ho, the co-founder and former president of BeiGene.
The company's strategic advisor
.
Regarding John and Peter joining Linglu as strategic consultants, the relevant person in charge of Linglu Pharmaceutical said that under the guidance of these two industry professionals, the company is expected to achieve rapid development
.
It is understood that John has a wealth of successful experience in developing advanced models and technology platforms for new treatments
.
Peter is a seasoned global drug discovery executive, clinical oncologist, and tumor pharmacology expert with deep expertise in translational medicine and building organizations across disease domains
.
In general, behind the frequent changes of senior executives of pharmaceutical companies is actually one of the responses made by pharmaceutical companies in response to the changes in the future pattern of the pharmaceutical industry
.
It is expected that with the further deepening of the reform of the domestic pharmaceutical industry, the competition among enterprises will continue to intensify, and the changes of senior executives of domestic and foreign pharmaceutical companies will become more frequent in the future, and the battle for talents will also be inevitable
.
.
From the current point of view, the changes in the executives of such pharmaceutical companies are becoming more frequent in 2022
.
On the 19th, Seri Medical issued an announcement stating that Liu Yuan applied for his resignation as the secretary of the company's board of directors and securities affairs representative due to personal reasons.
After resigning from the above-mentioned positions, he still serves as the deputy general manager
.
It is understood that Liu Yuan has held this position in the company since March 28, 2019
.
According to the data, Seri Medical was established on February 23, 2004.
Its main business is intensive sales, simple sales, and research and development, production and sales of independent in vitro diagnostic products
.
In recent years, its personnel changes are also more frequent
.
In August last year, a number of senior executives changed, involving the chief financial officer and general manager
.
On the 18th, Marc CROUTON, Chief Commercial Officer of the Fresenius Kabi Management Committee, and Ulf JASSON, Executive Vice President of the Asia Pacific Region, announced to the employees a personnel appointment, which will be executed by Fresenius Kabi China from February 1, 2022.
Zhuang Wenyan, vice president and general manager of Fresenius Kabihuarui Pharmaceuticals, temporarily leads the business of Feka in China
.
It is understood that Fresenius Kabi announced last month that Mr.
Ding Weibo, President of China, has decided to accept external development opportunities and will officially resign on February 1, 2022
.
According to Fresenius Kabi's original plan, after Ding Weibo leaves office, Ulf Jansson, Executive Vice President of Fresenius Kabi Asia Pacific, will also serve as President of Fresenius Kabi China
.
However, due to the ongoing epidemic, under the influence of this, Ulf Jansson's business trip to and from China has great uncertainty, so he made this new appointment
.
In addition, Fresenius Kabi has also promoted two business division heads this time.
Chen Guang, the current head of the parenteral nutrition and anesthesia division, will be promoted to the executive vice president of Fresenius Kabi Huarui Pharmaceuticals.
General Manager Shen Minyue, the current head of the General Business Division, will be promoted to General Manager of Beijing Fresenius Kabi Pharmaceutical Co.
, Ltd.
.
Linglu Pharmaceutical has also announced new personnel appointments recently, and its co-founder Zhang Xiaolei has become a full-time CEO
.
It is understood that Zhang Xiaolei will serve as the interim CEO of Linglu since May 2021; in addition, Linglu has also appointed Dr.
John Maraganore, the former founder and CEO of Alnylam, and Dr.
Peter Ho, the co-founder and former president of BeiGene.
The company's strategic advisor
.
Regarding John and Peter joining Linglu as strategic consultants, the relevant person in charge of Linglu Pharmaceutical said that under the guidance of these two industry professionals, the company is expected to achieve rapid development
.
It is understood that John has a wealth of successful experience in developing advanced models and technology platforms for new treatments
.
Peter is a seasoned global drug discovery executive, clinical oncologist, and tumor pharmacology expert with deep expertise in translational medicine and building organizations across disease domains
.
In general, behind the frequent changes of senior executives of pharmaceutical companies is actually one of the responses made by pharmaceutical companies in response to the changes in the future pattern of the pharmaceutical industry
.
It is expected that with the further deepening of the reform of the domestic pharmaceutical industry, the competition among enterprises will continue to intensify, and the changes of senior executives of domestic and foreign pharmaceutical companies will become more frequent in the future, and the battle for talents will also be inevitable
.
